Breakout to new highs getting closer - 35c-45c target, page-9

Should PYC turn down a multi-billion dollar deal if Moderna or some other mRNA vaccine phrama comes knocking on their door?

Remember VP-001 only gets US$1-2b per year income and helping a few thousand patients. An effective mRNA Covid vaccine with > 95% efficacy and extremely low toxicity using PYC CPP would save billions of people around the world. Would US$10-20b or $1 per dose be too much to ask for?

Dr. Rosenblatt is a member of Moderna Therapeutics’ Development Committee of the Board and Vaccine Acceleration Committee, and as a consultant to Moderna’s Chief Medical Officer. He has the knowledge and PYC has the goods!

The timing of his appointment to the PYC Board is very interesting to say the least.